Stock Code: 300558
Stock Abbreviation: Betta Pharmaceuticals
Announcement Number: 2026-044
Betta Pharmaceuticals Co., Ltd.
Announcement on the Publication of Clinical Research Results of Enasidenib Postoperative Adjuvant Therapy in The New England Journal of Medicine
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Today, Betta Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company") announced that its independently developed enasidenib hydrochloride capsules (brand name: Beimeina®, hereinafter referred to as "enasidenib") for the adjuvant treatment of IB-IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC) (hereinafter referred to as the "ELEVATE study") has been published online in the internationally authoritative medical journal "The New England Journal of Medicine" (Impact Factor: 84.5).
"The New England Journal of Medicine," founded in 1812, is one of the four major international authoritative medical journals, alongside "The Lancet," "JAMA," and "BMJ." The journal focuses on publishing Phase III registration studies with significant clinical translation value. The findings published in this journal serve as key references for updating clinical practice and revising diagnosis and treatment guidelines in the global oncology field. The publication of the ELEVATE study signifies the international authoritative recognition of the clinical value of enasidenib in postoperative adjuvant therapy, providing high-level evidence-based medicine for NSCLC patients in adjuvant treatment.
I. Basic Information of the Drug